Investors
We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.
Third Quarter 2025
Third quarter 2025 results were reviewed by management during a live audio webcast with the financial community on October 24, 2025. The presentation was followed by a Q&A session.
Press Releases
November 14, 2025
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
November 7, 2025
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
October 28, 2025
Press release: Sanofi successfully prices USD 3 billion of bond issue
Upcoming Events
3Nov
2023
Berenberg Pharma CFO Call Series 2025
16:30 - 17:30 CET (Virtual)
Conferences
12Nov
2025
Buy-side Healthcare CEO Summit
08:00 - 16:00 EST (Washington D.C.)
Conferences
13Nov
2025
Deutsche Bank R&D Call Series
16:30 - 17:30 CET (Virtual)
Conferences
30th Consecutive Year of Dividend Increase
Environment, Social, Governance
As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.
Contact Our Investor Relations Team
For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00